1. Home
  2. SLP vs ABCL Comparison

SLP vs ABCL Comparison

Compare SLP & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLP
  • ABCL
  • Stock Information
  • Founded
  • SLP 1996
  • ABCL 2012
  • Country
  • SLP United States
  • ABCL Canada
  • Employees
  • SLP N/A
  • ABCL N/A
  • Industry
  • SLP EDP Services
  • ABCL Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLP Technology
  • ABCL Health Care
  • Exchange
  • SLP Nasdaq
  • ABCL Nasdaq
  • Market Cap
  • SLP 675.9M
  • ABCL 772.9M
  • IPO Year
  • SLP 1997
  • ABCL 2020
  • Fundamental
  • Price
  • SLP $26.37
  • ABCL $2.14
  • Analyst Decision
  • SLP Buy
  • ABCL Strong Buy
  • Analyst Count
  • SLP 8
  • ABCL 4
  • Target Price
  • SLP $47.83
  • ABCL $8.33
  • AVG Volume (30 Days)
  • SLP 296.7K
  • ABCL 4.1M
  • Earning Date
  • SLP 07-01-2025
  • ABCL 05-08-2025
  • Dividend Yield
  • SLP 0.23%
  • ABCL N/A
  • EPS Growth
  • SLP N/A
  • ABCL N/A
  • EPS
  • SLP 0.36
  • ABCL N/A
  • Revenue
  • SLP $78,564,000.00
  • ABCL $23,114,000.00
  • Revenue This Year
  • SLP $30.21
  • ABCL N/A
  • Revenue Next Year
  • SLP $11.83
  • ABCL $36.62
  • P/E Ratio
  • SLP $73.23
  • ABCL N/A
  • Revenue Growth
  • SLP 21.49
  • ABCL N/A
  • 52 Week Low
  • SLP $23.01
  • ABCL $1.89
  • 52 Week High
  • SLP $50.11
  • ABCL $4.07
  • Technical
  • Relative Strength Index (RSI)
  • SLP 31.23
  • ABCL 50.63
  • Support Level
  • SLP $31.79
  • ABCL $1.98
  • Resistance Level
  • SLP $34.01
  • ABCL $2.08
  • Average True Range (ATR)
  • SLP 1.64
  • ABCL 0.10
  • MACD
  • SLP -0.40
  • ABCL 0.02
  • Stochastic Oscillator
  • SLP 0.78
  • ABCL 74.07

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: